Related Experiment Video
Updated: Dec 22, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
Published on: March 8, 2024
Abstract:
Early reports suggest that tocilizumab, an IL6 receptor-blocking antibody used to manage toxicities associated with chimeric antigen receptor T-cell therapy, may help control cytokine storms in people infected with COVID-19. Preliminary data from randomized trials are less clear-cut.
Insights
Tocilizumab, an IL6 receptor-blocking antibody, may help manage cytokine storms in COVID-19 patients. However, preliminary randomized trial data present less clear-cut evidence regarding its effectiveness.
Area of Science:
- Immunology
- Pharmacology
- Infectious Diseases
Background:
- Cytokine storms are a severe complication of COVID-19.
- Tocilizumab is an interleukin-6 (IL6) receptor antagonist.
- Tocilizumab is approved for managing cytokine release syndrome in CAR T-cell therapy.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Related Concept Videos
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
COPD: Management Using Bronchodilators and Corticosteroids